The pulmonary route as a way to drug repositioning in COVID-19 therapy
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
Texto Completo: | https://www.arca.fiocruz.br/handle/icict/53868 |
Resumo: | Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
id |
CRUZ_2efa4c741427942c740e2d8d68990ca4 |
---|---|
oai_identifier_str |
oai:www.arca.fiocruz.br:icict/53868 |
network_acronym_str |
CRUZ |
network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
repository_id_str |
2135 |
spelling |
Sarcinelli, MIchelle AlvaresSilva, Thalita Martins daSilva, Andressa Daniele ArticoPatricio, Beatriz Ferreira de CarvalhoPaiva, Flávia Costa Mendes deLima, Raissa Santos deSilva, Manuela Leal daRocha, Helvécio Vinícius Antunes2022-07-19T17:14:25Z2022-07-19T17:14:25Z2021SARCINELLI, Michelle Alvares et al. The pulmonary route as a way to drug repositioning in COVID-19 therapy. Journal of Drug Delivery Science and Technology , v. 63, 102430, p. 1-15, Feb. 2021.1773-2247https://www.arca.fiocruz.br/handle/icict/5386810.1016/j.jddst.2021.102430Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Laboratório de Micro e Nanotecnologia. Rio de Janeiro, RJ, Brasil / Rede Rio de Inovação em Nanossistemas para a Saúde. NanoSAÚDE/FAPERJ. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Laboratório de Micro e Nanotecnologia. Rio de Janeiro, RJ, Brasil / Rede Rio de Inovação em Nanossistemas para a Saúde. NanoSAÚDE/FAPERJ. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Famanguinhos. Programa de Pós-graduação em Pesquisa Translacional em Fármacos e Medicamentos. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Laboratório de Micro e Nanotecnologia. Rio de Janeiro, RJ, Brasil / Rede Rio de Inovação em Nanossistemas para a Saúde. NanoSAÚDE/FAPERJ. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Laboratório de Micro e Nanotecnologia. Rio de Janeiro, RJ, Brasil / Rede Rio de Inovação em Nanossistemas para a Saúde. NanoSAÚDE/FAPERJ. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Laboratório de Micro e Nanotecnologia. Rio de Janeiro, RJ, Brasil / Rede Rio de Inovação em Nanossistemas para a Saúde. NanoSAÚDE/FAPERJ. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Famanguinhos. Programa de Pós-graduação em Pesquisa Translacional em Fármacos e Medicamentos. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Programa de Pós-Graduação em Biologia Computacional e Sistemas,. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Programa de Pós-Graduação em Biologia Computacional e Sistemas,. Rio de Janeiro, RJ, Brasil / Universidade Federal Do Rio de Janeiro. Instituto de Biodiversidade e Sustentabilidade (NUPEM), Macaé, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Laboratório de Micro e Nanotecnologia. Rio de Janeiro, RJ, Brasil / Rede Rio de Inovação em Nanossistemas para a Saúde. NanoSAÚDE/FAPERJ. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Famanguinhos. Programa de Pós-graduação em Pesquisa Translacional em Fármacos e Medicamentos. Rio de Janeiro, RJ, Brasil.Introduction: The outbreak of the disease caused by the new coronavirus (COVID-19) has been affecting society’s routine and its patterns of interaction worldwide, in addition to the impact on the global economy. To date, there is still no clinically effective treatment for this comorbidity, and drug repositioning might be a good strategy considering the established clinical safety profile. In this context, since COVID-19 affects the respiratory tract, a promising approach would be the pulmonary drug delivery. Objective: Identify repurposing drug candidates for the treatment of COVID-19 based on the data of ongoing clinical trials and in silico studies and also assess their potential to be applied in formulations for pulmonary administration. Method: A integrative literature review was conducted between June and July 2020, by extracting the results from Clinical Trials, PubMed, Web of Science and Science Direct databases. Results: By crossing the results obtained from diverse sources, 21 common drugs were found, from which only 4 drugs presented studies of pulmonary release formulations, demonstrating the need for greater investment and incentive in this field. Conclusion: Even though the lung is a target that facilitates viral infection and replication, formulations for pulmonary delivery of suitable drugs are still lacking for COVID-19 treatment. However, it is indisputable that the pandemic constitutes a concrete demand, with a profound impact on public health, and that, with the appropriate investments, it will give the pharmaceutical industry an opportunity to reinforce the pulmonary delivery field.engElsevierSARS-CoV-2CoronavírusFormulações pulmonaresAdministração de drogas pulmonaresReaproveitamento de drogasSARS-CoV-2CoronavirusPulmonary formulationsPulmonary drug deliveryDrug repurposingThe pulmonary route as a way to drug repositioning in COVID-19 therapyinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/53868/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALRaissaLima_ManuelaLealSilva_etal_IOC_2021.pdfRaissaLima_ManuelaLealSilva_etal_IOC_2021.pdfapplication/pdf3299719https://www.arca.fiocruz.br/bitstream/icict/53868/2/RaissaLima_ManuelaLealSilva_etal_IOC_2021.pdfa9b0e4a17967cd85e58e18461b109ab3MD52icict/538682022-11-20 12:27:56.913oai:www.arca.fiocruz.br:icict/53868Q0VTU8ODTyBOw4NPIEVYQ0xVU0lWQSBERSBESVJFSVRPUyBBVVRPUkFJUwoKQW8gYWNlaXRhciBvcyBURVJNT1MgZSBDT05EScOHw5VFUyBkZXN0YSBDRVNTw4NPLCBvIEFVVE9SIGUvb3UgVElUVUxBUiBkZSBkaXJlaXRvcwphdXRvcmFpcyBzb2JyZSBhIE9CUkEgZGUgcXVlIHRyYXRhIGVzdGUgZG9jdW1lbnRvOgoKKDEpIENFREUgZSBUUkFOU0ZFUkUsIHRvdGFsIGUgZ3JhdHVpdGFtZW50ZSwgw6AgRklPQ1JVWiAtIEZVTkRBw4fDg08gT1NXQUxETyBDUlVaLCBlbQpjYXLDoXRlciBwZXJtYW5lbnRlLCBpcnJldm9nw6F2ZWwgZSBOw4NPIEVYQ0xVU0lWTywgdG9kb3Mgb3MgZGlyZWl0b3MgcGF0cmltb25pYWlzIE7Dg08KQ09NRVJDSUFJUyBkZSB1dGlsaXphw6fDo28gZGEgT0JSQSBhcnTDrXN0aWNhIGUvb3UgY2llbnTDrWZpY2EgaW5kaWNhZGEgYWNpbWEsIGluY2x1c2l2ZSBvcyBkaXJlaXRvcwpkZSB2b3ogZSBpbWFnZW0gdmluY3VsYWRvcyDDoCBPQlJBLCBkdXJhbnRlIHRvZG8gbyBwcmF6byBkZSBkdXJhw6fDo28gZG9zIGRpcmVpdG9zIGF1dG9yYWlzLCBlbQpxdWFscXVlciBpZGlvbWEgZSBlbSB0b2RvcyBvcyBwYcOtc2VzOwoKKDIpIEFDRUlUQSBxdWUgYSBjZXNzw6NvIHRvdGFsIG7Do28gZXhjbHVzaXZhLCBwZXJtYW5lbnRlIGUgaXJyZXZvZ8OhdmVsIGRvcyBkaXJlaXRvcyBhdXRvcmFpcwpwYXRyaW1vbmlhaXMgbsOjbyBjb21lcmNpYWlzIGRlIHV0aWxpemHDp8OjbyBkZSBxdWUgdHJhdGEgZXN0ZSBkb2N1bWVudG8gaW5jbHVpLCBleGVtcGxpZmljYXRpdmFtZW50ZSwKb3MgZGlyZWl0b3MgZGUgZGlzcG9uaWJpbGl6YcOnw6NvIGUgY29tdW5pY2HDp8OjbyBww7pibGljYSBkYSBPQlJBLCBlbSBxdWFscXVlciBtZWlvIG91IHZlw61jdWxvLAppbmNsdXNpdmUgZW0gUmVwb3NpdMOzcmlvcyBEaWdpdGFpcywgYmVtIGNvbW8gb3MgZGlyZWl0b3MgZGUgcmVwcm9kdcOnw6NvLCBleGliacOnw6NvLCBleGVjdcOnw6NvLApkZWNsYW1hw6fDo28sIHJlY2l0YcOnw6NvLCBleHBvc2nDp8OjbywgYXJxdWl2YW1lbnRvLCBpbmNsdXPDo28gZW0gYmFuY28gZGUgZGFkb3MsIHByZXNlcnZhw6fDo28sIGRpZnVzw6NvLApkaXN0cmlidWnDp8OjbywgZGl2dWxnYcOnw6NvLCBlbXByw6lzdGltbywgdHJhZHXDp8OjbywgZHVibGFnZW0sIGxlZ2VuZGFnZW0sIGluY2x1c8OjbyBlbSBub3ZhcyBvYnJhcyBvdQpjb2xldMOibmVhcywgcmV1dGlsaXphw6fDo28sIGVkacOnw6NvLCBwcm9kdcOnw6NvIGRlIG1hdGVyaWFsIGRpZMOhdGljbyBlIGN1cnNvcyBvdSBxdWFscXVlciBmb3JtYSBkZQp1dGlsaXphw6fDo28gbsOjbyBjb21lcmNpYWw7CgooMykgUkVDT05IRUNFIHF1ZSBhIGNlc3PDo28gYXF1aSBlc3BlY2lmaWNhZGEgY29uY2VkZSDDoCBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPCkNSVVogbyBkaXJlaXRvIGRlIGF1dG9yaXphciBxdWFscXVlciBwZXNzb2Eg4oCTIGbDrXNpY2Egb3UganVyw61kaWNhLCBww7pibGljYSBvdSBwcml2YWRhLCBuYWNpb25hbCBvdQplc3RyYW5nZWlyYSDigJMgYSBhY2Vzc2FyIGUgdXRpbGl6YXIgYW1wbGFtZW50ZSBhIE9CUkEsIHNlbSBleGNsdXNpdmlkYWRlLCBwYXJhIHF1YWlzcXVlcgpmaW5hbGlkYWRlcyBuw6NvIGNvbWVyY2lhaXM7CgooNCkgREVDTEFSQSBxdWUgYSBvYnJhIMOpIGNyaWHDp8OjbyBvcmlnaW5hbCBlIHF1ZSDDqSBvIHRpdHVsYXIgZG9zIGRpcmVpdG9zIGFxdWkgY2VkaWRvcyBlIGF1dG9yaXphZG9zLApyZXNwb25zYWJpbGl6YW5kby1zZSBpbnRlZ3JhbG1lbnRlIHBlbG8gY29udGXDumRvIGUgb3V0cm9zIGVsZW1lbnRvcyBxdWUgZmF6ZW0gcGFydGUgZGEgT0JSQSwKaW5jbHVzaXZlIG9zIGRpcmVpdG9zIGRlIHZveiBlIGltYWdlbSB2aW5jdWxhZG9zIMOgIE9CUkEsIG9icmlnYW5kby1zZSBhIGluZGVuaXphciB0ZXJjZWlyb3MgcG9yCmRhbm9zLCBiZW0gY29tbyBpbmRlbml6YXIgZSByZXNzYXJjaXIgYSBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPIENSVVogZGUKZXZlbnR1YWlzIGRlc3Blc2FzIHF1ZSB2aWVyZW0gYSBzdXBvcnRhciwgZW0gcmF6w6NvIGRlIHF1YWxxdWVyIG9mZW5zYSBhIGRpcmVpdG9zIGF1dG9yYWlzIG91CmRpcmVpdG9zIGRlIHZveiBvdSBpbWFnZW0sIHByaW5jaXBhbG1lbnRlIG5vIHF1ZSBkaXogcmVzcGVpdG8gYSBwbMOhZ2lvIGUgdmlvbGHDp8O1ZXMgZGUgZGlyZWl0b3M7CgooNSkgQUZJUk1BIHF1ZSBjb25oZWNlIGEgUG9sw610aWNhIEluc3RpdHVjaW9uYWwgZGUgQWNlc3NvIEFiZXJ0byBkYSBGSU9DUlVaIC0gRlVOREHDh8ODTwpPU1dBTERPIENSVVogZSBhcyBkaXJldHJpemVzIHBhcmEgbyBmdW5jaW9uYW1lbnRvIGRvIHJlcG9zaXTDs3JpbyBpbnN0aXR1Y2lvbmFsIEFSQ0EuCgpBIFBvbMOtdGljYSBJbnN0aXR1Y2lvbmFsIGRlIEFjZXNzbyBBYmVydG8gZGEgRklPQ1JVWiAtIEZVTkRBw4fDg08gT1NXQUxETyBDUlVaIHJlc2VydmEKZXhjbHVzaXZhbWVudGUgYW8gQVVUT1Igb3MgZGlyZWl0b3MgbW9yYWlzIGUgb3MgdXNvcyBjb21lcmNpYWlzIHNvYnJlIGFzIG9icmFzIGRlIHN1YSBhdXRvcmlhCmUvb3UgdGl0dWxhcmlkYWRlLCBzZW5kbyBvcyB0ZXJjZWlyb3MgdXN1w6FyaW9zIHJlc3BvbnPDoXZlaXMgcGVsYSBhdHJpYnVpw6fDo28gZGUgYXV0b3JpYSBlIG1hbnV0ZW7Dp8OjbwpkYSBpbnRlZ3JpZGFkZSBkYSBPQlJBIGVtIHF1YWxxdWVyIHV0aWxpemHDp8Ojby4KCkEgUG9sw610aWNhIEluc3RpdHVjaW9uYWwgZGUgQWNlc3NvIEFiZXJ0byBkYSBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPIENSVVoKcmVzcGVpdGEgb3MgY29udHJhdG9zIGUgYWNvcmRvcyBwcmVleGlzdGVudGVzIGRvcyBBdXRvcmVzIGNvbSB0ZXJjZWlyb3MsIGNhYmVuZG8gYW9zIEF1dG9yZXMKaW5mb3JtYXIgw6AgSW5zdGl0dWnDp8OjbyBhcyBjb25kacOnw7VlcyBlIG91dHJhcyByZXN0cmnDp8O1ZXMgaW1wb3N0YXMgcG9yIGVzdGVzIGluc3RydW1lbnRvcy4KRepositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352022-11-20T15:27:56Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
dc.title.pt_BR.fl_str_mv |
The pulmonary route as a way to drug repositioning in COVID-19 therapy |
title |
The pulmonary route as a way to drug repositioning in COVID-19 therapy |
spellingShingle |
The pulmonary route as a way to drug repositioning in COVID-19 therapy Sarcinelli, MIchelle Alvares SARS-CoV-2 Coronavírus Formulações pulmonares Administração de drogas pulmonares Reaproveitamento de drogas SARS-CoV-2 Coronavirus Pulmonary formulations Pulmonary drug delivery Drug repurposing |
title_short |
The pulmonary route as a way to drug repositioning in COVID-19 therapy |
title_full |
The pulmonary route as a way to drug repositioning in COVID-19 therapy |
title_fullStr |
The pulmonary route as a way to drug repositioning in COVID-19 therapy |
title_full_unstemmed |
The pulmonary route as a way to drug repositioning in COVID-19 therapy |
title_sort |
The pulmonary route as a way to drug repositioning in COVID-19 therapy |
author |
Sarcinelli, MIchelle Alvares |
author_facet |
Sarcinelli, MIchelle Alvares Silva, Thalita Martins da Silva, Andressa Daniele Artico Patricio, Beatriz Ferreira de Carvalho Paiva, Flávia Costa Mendes de Lima, Raissa Santos de Silva, Manuela Leal da Rocha, Helvécio Vinícius Antunes |
author_role |
author |
author2 |
Silva, Thalita Martins da Silva, Andressa Daniele Artico Patricio, Beatriz Ferreira de Carvalho Paiva, Flávia Costa Mendes de Lima, Raissa Santos de Silva, Manuela Leal da Rocha, Helvécio Vinícius Antunes |
author2_role |
author author author author author author author |
dc.contributor.author.fl_str_mv |
Sarcinelli, MIchelle Alvares Silva, Thalita Martins da Silva, Andressa Daniele Artico Patricio, Beatriz Ferreira de Carvalho Paiva, Flávia Costa Mendes de Lima, Raissa Santos de Silva, Manuela Leal da Rocha, Helvécio Vinícius Antunes |
dc.subject.other.pt_BR.fl_str_mv |
SARS-CoV-2 Coronavírus Formulações pulmonares Administração de drogas pulmonares Reaproveitamento de drogas |
topic |
SARS-CoV-2 Coronavírus Formulações pulmonares Administração de drogas pulmonares Reaproveitamento de drogas SARS-CoV-2 Coronavirus Pulmonary formulations Pulmonary drug delivery Drug repurposing |
dc.subject.en.pt_BR.fl_str_mv |
SARS-CoV-2 Coronavirus Pulmonary formulations Pulmonary drug delivery Drug repurposing |
description |
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
publishDate |
2021 |
dc.date.issued.fl_str_mv |
2021 |
dc.date.accessioned.fl_str_mv |
2022-07-19T17:14:25Z |
dc.date.available.fl_str_mv |
2022-07-19T17:14:25Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
SARCINELLI, Michelle Alvares et al. The pulmonary route as a way to drug repositioning in COVID-19 therapy. Journal of Drug Delivery Science and Technology , v. 63, 102430, p. 1-15, Feb. 2021. |
dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/53868 |
dc.identifier.issn.pt_BR.fl_str_mv |
1773-2247 |
dc.identifier.doi.none.fl_str_mv |
10.1016/j.jddst.2021.102430 |
identifier_str_mv |
SARCINELLI, Michelle Alvares et al. The pulmonary route as a way to drug repositioning in COVID-19 therapy. Journal of Drug Delivery Science and Technology , v. 63, 102430, p. 1-15, Feb. 2021. 1773-2247 10.1016/j.jddst.2021.102430 |
url |
https://www.arca.fiocruz.br/handle/icict/53868 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Elsevier |
publisher.none.fl_str_mv |
Elsevier |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
collection |
Repositório Institucional da FIOCRUZ (ARCA) |
bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/53868/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/53868/2/RaissaLima_ManuelaLealSilva_etal_IOC_2021.pdf |
bitstream.checksum.fl_str_mv |
5a560609d32a3863062d77ff32785d58 a9b0e4a17967cd85e58e18461b109ab3 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
_version_ |
1798324810970824704 |